BACKGROUND: Eukaryotic translation initiation factor 4-gamma 1 (EIF4G1) gene mutations have recently been reported in autosomal dominant, late-onset Parkinson's disease (LOPD). We carried out genetic analysis to determine the prevalence of EIF4G1 variants in an ethnic Chinese population and to better understand the association between EIF4G1 and PD. METHODS: We conducted a comprehensive genetic analysis of EIF4G1 in a cohort of 29 probands of autosomal dominant, LOPD families. Polymerase chain reaction (PCR) analysis and sequencing was carried out of the entire EIF4G1 exonic regions and exon-intron boundaries. Specific mutation and exonic variants were chosen for further sequencing in a case-control study including 503 sporadic PD and 508 healthy controls. Statistical significance was analyzed by the Chi-square test. RESULTS: Our analysis revealed three exonic variants (rs2230571, rs13319149 and rs2178403) and eight intronic variants across the entire EIF4G1 gene. No reported mutations were detected in EIF4G1 exonic regions. The synonymous coding variant rs2230571 in exon 27 and the eight intronic variants were not used for further sequencing, but the specific mutation c.3614G > A (p.R1205H) and the two nonsynonymous variants (rs13319149 and rs2178403) were chosen for further analysis in a case-control study. None of the 503 sporadic PD or 508 healthy controls carried p.R1205H, and there was no statistical significance in rs2178403 genotype or allele frequencies in EIF4G1 between the PD cases and the healthy controls (p = 0.184 and p = 0.774, respectively; Chi-square test). The rs13319149 genotype in all PD cases and healthy controls was GG. CONCLUSIONS: Our data indicate that in an ethnic Chinese population, the pathogenic mutation p.R1205H in EIF4G1 is not common and that EIF4G1 exonic variants rs2178403 and rs13319149 are not associated with PD. EIF4G1 does not appear to be a frequent cause of PD in this ethnic Chinese population.
BACKGROUND:Eukaryotic translation initiation factor 4-gamma 1 (EIF4G1) gene mutations have recently been reported in autosomal dominant, late-onset Parkinson's disease (LOPD). We carried out genetic analysis to determine the prevalence of EIF4G1 variants in an ethnic Chinese population and to better understand the association between EIF4G1 and PD. METHODS: We conducted a comprehensive genetic analysis of EIF4G1 in a cohort of 29 probands of autosomal dominant, LOPD families. Polymerase chain reaction (PCR) analysis and sequencing was carried out of the entire EIF4G1 exonic regions and exon-intron boundaries. Specific mutation and exonic variants were chosen for further sequencing in a case-control study including 503 sporadic PD and 508 healthy controls. Statistical significance was analyzed by the Chi-square test. RESULTS: Our analysis revealed three exonic variants (rs2230571, rs13319149 and rs2178403) and eight intronic variants across the entire EIF4G1 gene. No reported mutations were detected in EIF4G1 exonic regions. The synonymous coding variant rs2230571 in exon 27 and the eight intronic variants were not used for further sequencing, but the specific mutation c.3614G > A (p.R1205H) and the two nonsynonymous variants (rs13319149 and rs2178403) were chosen for further analysis in a case-control study. None of the 503 sporadic PD or 508 healthy controls carried p.R1205H, and there was no statistical significance in rs2178403 genotype or allele frequencies in EIF4G1 between the PD cases and the healthy controls (p = 0.184 and p = 0.774, respectively; Chi-square test). The rs13319149 genotype in all PD cases and healthy controls was GG. CONCLUSIONS: Our data indicate that in an ethnic Chinese population, the pathogenic mutation p.R1205H in EIF4G1 is not common and that EIF4G1 exonic variants rs2178403 and rs13319149 are not associated with PD. EIF4G1 does not appear to be a frequent cause of PD in this ethnic Chinese population.
Parkinson’s disease (PD) is the second most common neurodegenerative movement disorder and is clinically characterized by the cardinal features of bradykinesia, resting tremor, rigidity, postural instability and responsiveness to dopaminergic therapy. Most PDpatients are sporadic but approximately 5–10% are familial [1]. Although the etiology of PD still remains elusive, certain genes are known to influence PD susceptibility, for example, autosomal dominant PD is associated with SNCA[2], LRRK2[3], UCHL1[4] and VPS35[5,6], recessive parkinsonism with PRKN[7], PINK1[8] and DJ-1[9], and more complex forms of recessive parkinsonism with ATP13A2[10], PLA2G6[11] and FBXO7[12]. Several techniques have been used to identify candidate genes in familial PD, including classic linkage analysis, positional cloning studies and recent exome sequencing [2,5,6,13].Recently, Chartier-Harlin et al. [14,15] performed genome-wide linkage analysis of a multi-incident French family presenting with autosomal dominant, late-onset PD (LOPD). They found that the mutation c.3614G > A (p.R1205H) in EIF4G1, encoding eukaryotic translation initiation factor 4G1 (eIF4G1), a component of the translation initiation complex eukaryotic translation initiation factor 4F (eIF4F), caused the familial LOPD. The translation initiation complex is a large family [16,17], including eukaryotic translation initiation factor 4E (eIF4E) and eukaryotic translation initiation factor 3e (eIF3e) that interact with each other and conduct normal translation initiation activity [14,18,19]. In the Chartier-Harlin study [14], it was predicted that mutations p.A502V and p.R1205H disrupt eIF4G1 binding to eIF4E or eIF3e, resulting in PD. Subsequent sequencing and genotyping analysis also identified different EIF4G1 mutations in affected subjects with familial parkinsonism and idiopathic Lewy body disease in different populations.To obtain a comprehensive view of the prevalence of EIF4G1 variants in an ethnic Chinese population, we conducted a comprehensive genetic screening of EIF4G1 in a Han Chinese group of subjects.
Methods
Patients
The study comprised 29 probands of PD families compatible with autosomal dominant inheritance (two or more PD cases in at least two consecutive generations) and 503 sporadic PDpatients of Chinese Han ethnicity from Hunan, Hubei, Jiangxi, Sichuan and Chongqing provinces of China. All patients were consecutively recruited from the Department of Neurology of Xiangya Hospital (Central South University, State Key Laboratory of Medical Genetics of China) and the Neurodegenerative Disorders Research Center. A standard clinical neurological examination was performed for all patients by two neurologists, and a diagnosis of idiopathic PD was made according to the United Kingdom PD Brain Bank Criteria [20].There were 13 male and 16 female PDpatients among the 29 autosomal dominant, LOPD probands, with a mean age at onset of 50.33 ± 9.56 years (range, 41–63 years). Of the 503 sporadic PDpatients, 269 were male and 234 were female with a mean age at onset of 55.25 ± 12.21 years (range, 22–81 years). The case–control study also included 508 healthy controls (268 males and 240 females; average age at examination, 56.95 ± 15.20 years, range, 25–88 years) matched for age, gender, ethnicity and area of residence. The control subjects were healthy people from the Xiangya Hospital Medical Center, and healthy volunteers with no history of neurodegenerative diseases. A standard clinical neurological examination was performed on all control subjects, and a diagnosis of possible idiopathic PD was excluded according to the United Kingdom PD Brain Bank Criteria. There was no statistically significant difference in age or gender between patients and controls (p > 0.05, using Chi-square test). The study protocol was approved by the Ethics Committee of Central South University and written informed consent was obtained from all patients and controls.
Genetic analysis
Genomic DNA was extracted from peripheral blood using standard protocols. Polymerase chain reaction (PCR) analysis was carried out using 20 primer pairs (Additional file 1: Table S1, available online), and each PCR product was purified and directly sequenced in both forward and reverse directions on an ABI 3100 automated sequencer (Applied Biosystems, Foster City, CA). We initially sequenced the entire EIF4G1 exonic regions and exon-intron boundaries of the 29 probands of autosomal dominant, LOPD. Sequence alignment and analysis were carried out with Chromas 2.12 software (Technelysium Pty, Inc., Queensland, Australia).
Statistical analysis
Allele and genotype frequencies of PD and control groups were analyzed using the Chi-square test with SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). A two-tailed test p-value of <0.05 was considered statistically significant.
Results
We identified three exonic variants and eight intronic variants across the entire EIF4G1 gene (Table 1). No reported mutations were detected in the EIF4G1 exonic regions in any of the 29 probands. One of the three exonic variants (exon 25, rs2230571) was synonymous, the other two (rs13319149 and rs2178403) were nonsynonymous.
Table 1
gene variants in 29 probands of LOPD families
Exonic/intronic variants
Accession number
Nucleotide changea
Amino acid change
Frequency of variant in LOPD families (%)
1
Intron 2
rs73187631
IVS2-182 a > t
7.41
2
Intron 3
novel
IVS3 -44 a > g
1.85
3
Intron 4
novel
IVS4 + 115 g > a
3.70
4
Exon 7
rs13319149
c.481A > G
T161A
100
5
Intron 9
rs9846954
IVS9 + 93 a > t
25.93
6
Intron 9
novel
IVS9 + 75 indelb
7.41
7
Intron 9
rs4912537
IVS9-100 c > t
14.81
8
Exon 10
rs2178403
c.1294A > G
M432V
55.56
9
Intron 15
1KG 3 184041398
IVS15 + 17 c > t
1.85
10
Intron 18
1KG 3 184043002
IVS18 + 100 g > t
1.85
11
Exon 27
rs2230571
c.4005C > T
H1335H
18.52
a Human EIF4G1 cDNA sequence (RefSeq Accession number NM_198241.2) was used as the reference sequence.
gene variants in 29 probands of LOPD familiesa HumanEIF4G1 cDNA sequence (RefSeq Accession number NM_198241.2) was used as the reference sequence.b indel : acttgaac deletion; tgggtaccagagaa insertion. (i.e. acttgaac > ggtaccagagaa).Neither the synonymous variant nor the eight intronic variants could be sequenced, but the specific mutation p.R1205H and the two nonsynonymous variants underwent sequencing analysis in the 503 sporadic PDpatients and 508 controls. None of the patients or controls carried the specific mutation p.R1205H. The nonsynonymous exonic variant rs2178403 was in Hardy-Weinberg equilibrium in both the patient and control groups using a goodness-of-fit Chi-square test. Genotype and allele frequencies of rs2178403 for all subjects are shown in Table 2. No statistically significant differences were observed regarding rs2178403 genotype or allele frequency between patients and controls (p = 0.184 and p = 0.774, respectively). Regarding the nonsynonymous exonic variant rs13319149, all patient and control genotypes were GG.
Table 2
Genotype and allele frequencies of rs2178403 in PD and controls in Han Chinese
N
Genotype (%)
Allele (%)
AA
AG
GG
P value(df )
A
G
P value (df , OR)
Patients 503
74(14.7)
226(44.9)
203(40.4)
0.184a (1)
374(37.2)
632(62.8)
0.774b (1, 1.027)
Controls 508
87 (17.1)
210(41.4)
211(41.5)
384(37.8)
632(62.2)
P Values after correcting by binary logistic regression with age and gender using SPSS 17.0: a p = 0.713, bp = 0.702.
Genotype and allele frequencies of rs2178403 in PD and controls in Han ChineseP Values after correcting by binary logistic regression with age and gender using SPSS 17.0: a p = 0.713, bp = 0.702.
Discussion
EIF4G1 was confirmed as a candidate PD gene by Chartier-Harlin et al. [14,15], but recently three other groups identified EIF4G1 mutations in both PDpatients and healthy controls [21-23]. This raises questions about the causality of the gene with regard to PD. In our comprehensive genetic analysis of EIF4G1, we also obtained similar negative results. The specific mutation p.R1205H, first identified by Chartier-Harlin, is important in PD for regulating cell survival in response to stressors [14,15]. However, it was absent from all of our 503 sporadic PD cases and 508 healthy controls suggesting that different populations may have different pathogenic mutations. Alternatively, the effect of the same mutation may differ in different populations, as indicated by the presence of mutation p.R1205H in control individuals of a Central European population shown by Schulte et al. [23].In the present study, exonic variants rs13319149 and rs2178403 showed no significant difference in either genotype or allele frequencies between PDpatients and controls, suggesting that they are probably benign polymorphisms. Although EIF4G1 is considered a pathogenic gene of LOPD, our 29 probands were not typical of LOPD as the average age of onset was 50.33 ± 9.56 years. This may contribute to our negative results, together with the fact that our sample size was relatively small. Further larger-scale genetic studies should therefore be performed to validate our findings.
Conclusions
To our knowledge, this is the first study to assess the frequency of EIF4G1 variants in a cohort of Chinese PDpatients and controls. Our results suggest that in this ethnic Chinese population, the pathogenic mutation p.R1205H in EIF4G1 is not common and that nonsynonymous exonic variants rs2178403 and rs13319149 are not associated with PD. Thus, it appears that EIF4G1 is not a frequent cause of PD in this ethnic Chinese population. Further large scale genetic and functional studies would be useful to establish EIF4G1 associations with PD.
The authors declare that they have no competing interests.
Authors’ contributions
KL performed the genotyping, statistical analysis, and drafted the manuscript. MXL, ZYL, ZHL, YT, CYS, and KX contributed to the collection of materials, participated in the study design and coordination, and drafted the manuscript. BST, JFG and XXY conceived the study, participated in its conceptual design and coordination, and drafted the manuscript. All authors read and approved the final manuscript.
Pre-publication history
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2377/13/38/prepub
Authors: E Leroy; R Boyer; G Auburger; B Leube; G Ulm; E Mezey; G Harta; M J Brownstein; S Jonnalagada; T Chernova; A Dehejia; C Lavedan; T Gasser; P J Steinbach; K D Wilkinson; M H Polymeropoulos Journal: Nature Date: 1998-10-01 Impact factor: 49.962
Authors: T Kitada; S Asakawa; N Hattori; H Matsumine; Y Yamamura; S Minoshima; M Yokochi; Y Mizuno; N Shimizu Journal: Nature Date: 1998-04-09 Impact factor: 49.962
Authors: Alfredo Ramirez; André Heimbach; Jan Gründemann; Barbara Stiller; Dan Hampshire; L Pablo Cid; Ingrid Goebel; Ammar F Mubaidin; Abdul-Latif Wriekat; Jochen Roeper; Amir Al-Din; Axel M Hillmer; Meliha Karsak; Birgit Liss; C Geoffrey Woods; Maria I Behrens; Christian Kubisch Journal: Nat Genet Date: 2006-09-10 Impact factor: 38.330
Authors: Aaron K LeFebvre; Nadejda L Korneeva; Marjan Trutschl; Urska Cvek; Roy D Duzan; Christopher A Bradley; John W B Hershey; Robert E Rhoads Journal: J Biol Chem Date: 2006-06-09 Impact factor: 5.157
Authors: Coro Paisan-Ruiz; Kailash P Bhatia; Abi Li; Dena Hernandez; Mary Davis; Nick W Wood; John Hardy; Henry Houlden; Andrew Singleton; Susanne A Schneider Journal: Ann Neurol Date: 2009-01 Impact factor: 11.274
Authors: Prabhjyot Saini; Uladzislau Rudakou; Eric Yu; Jennifer A Ruskey; Farnaz Asayesh; Sandra B Laurent; Dan Spiegelman; Stanley Fahn; Cheryl Waters; Oury Monchi; Yves Dauvilliers; Nicolas Dupré; Lior Greenbaum; Sharon Hassin-Baer; Alberto J Espay; Guy A Rouleau; Roy N Alcalay; Edward A Fon; Ronald B Postuma; Ziv Gan-Or Journal: Neurobiol Aging Date: 2020-10-31 Impact factor: 4.673